Covalent Inhibition in Drug Discovery
Open accessAbstract
Although covalent inhibitors have been used as therapeutics for more than a century, there has been general resistance in the pharmaceutical industry against their further development due to safety concerns. This inclination has recently been reverted after the development of a wide variety of covalent inhibitors to address human health conditions along with the US Food and Drug Administration (FDA) approval of several covalent therapeutics for use in humans. Along with this exciting resurrection of an old drug discovery concept, this review surveys enzymes that can be targeted by covalent inhibitors for the treatment of human diseases. We focus on protein kinases, RAS proteins, and a few other enzymes that have been studied extensively as targets for covalent inhibition, with the aim to address challenges in designing effective covalent drugs and to provide suggestions in the area that have yet to be explored.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Concerns about assay interference and poor selectivity historically discouraged investigation of reactive molecules.
“Historically, concerns about the interference of these reactive molecules with biological assays and potential lack of selectivity often discouraged further investigation2,3.”
From Advances in covalent drug discovery (2022) · cites this paper as [3]
Nirmatrelvir covalently inhibits SARS-CoV-2 main protease.
“Nirmatrelvir (Table 1) covalently inhibits the Mpro of SARS-CoV-2 (ref.3).”
From Advances in covalent drug discovery (2022) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,815 · see citing works
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,262 · see citing works
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,585 · see citing works
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306 · see citing works
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · see citing works
Stamos, J. L., Sliwkowski, M. X., & Eigenbrot, C. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,594 · see citing works
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589 · see citing works
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,483 · see citing works
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,460 · see citing works
Cysteine cathepsins: From structure, function and regulation to new frontiers
Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., & Turk, D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.10.002 · Cited by 1,377 · see citing works
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,268 · see citing works
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,203 · see citing works
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · see citing works
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,012 · see citing works
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · see citing works
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 933 · see citing works
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 902 · see citing works
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N. P., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B. M., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 865 · see citing works
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730 · see citing works
Halogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723 · see citing works
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 647 · see citing works
Caspases: pharmacological manipulation of cell death
Lavrik, I. N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26252 · Cited by 646 · see citing works
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · see citing works
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · see citing works
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578 · see citing works
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K. M., Bar‐Sagi, D., & Philips, M. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 557 · see citing works
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 548 · see citing works
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534 · see citing works
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity
Shahbazian, D., Roux, P. P., Mieulet, V., Cohen, M. S., Raught, B., Taunton, J., Hershey, J. W. B., Blenis, J., Pende, M., & Sonenberg, N. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601166 · Cited by 532 · see citing works
Kahan, J. S., Kahan, F. M., Goegelman, R. T., et al. (1979) · The Journal of Antibiotics · doi:10.7164/antibiotics.32.1 · Cited by 516 · see citing works
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 509 · see citing works
Gavine, P. R., Mooney, L. M., Kilgour, E., Thomas, A. P., Al-Kadhimi, K. J., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 507 · see citing works
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 496 · see citing works
Loll, P. J., Picot, D., & Garavito, R. M. (1995) · Nature Structural Biology · doi:10.1038/nsb0895-637 · Cited by 490 · see citing works
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Douget, M. L., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., SCHMID, H. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 485 · see citing works
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W. A., Desmarais, S., Duong, L. T., Falgueyret, J., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 479 · see citing works
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A. R., Clarke, S. E., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H., Naisbitt, D. J., Nelson, S. D., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 466 · see citing works
Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Vasiljeva, O. S., Reinheckel, T., Peters, C., Turk, D., Türk, V., & Turk, B. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780162962 · Cited by 452 · see citing works
Sequist, L. V. D., Besse, B., Lynch, T. J., Miller, V. A., Wong, K., Gitlitz, B. J., Eaton, K. D., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 432 · see citing works
Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor
Schindler, T. H., Sicheri, F., Pico, A. R., Gazit, A., Levitzki, A., & Kuriyan, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80357-3 · Cited by 429 · see citing works
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 428 · see citing works
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A. M., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 424 · see citing works
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
Barnett, A. H. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 389 · see citing works
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 385 · see citing works
Mikhaylov, G., Mikac, U., Магаева, А. А., Itin, V. I., Naiden, E. P., Psakhye, I., Babes, L., Reinheckel, T., Peters, C., Zeiser, R., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.112 · Cited by 382 · see citing works
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374 · see citing works
Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362 · see citing works
Caspase activation, inhibition, and reactivation: A mechanistic view
Shi, Y. (2004) · Protein Science · doi:10.1110/ps.04789804 · Cited by 361 · see citing works
Bone, H. G., McClung, M. R., Roux, C., Recker, R. R., Eisman, J. A., Verbruggen, N., Hustad, C. M., DaSilva, C. A., Santora, A. C., & Ince, B. A. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091035 · Cited by 334 · see citing works
Guerciolini, R. (1997) · PubMed · Cited by 326 · see citing works
Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323 · see citing works
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 312 · see citing works
Cysteine cathepsin proteases as pharmacological targets in cancer
Palermo, C., & Joyce, J. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.011 · Cited by 310 · see citing works
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Wang, S., Cang, S., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0268-z · Cited by 302 · see citing works
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Furman, R. R., Cheng, S., Lu, P., Setty, M., Perez, A. R., Guo, A., Racchumi, J., Xu, G., Wu, H., Ma, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1402716 · Cited by 300 · see citing works
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300 · see citing works
Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281 · see citing works
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A. C., Witucki, L. A., Kraybill, B. C., Shimizu, E., Tsien, J. Z., Ubersax, J. A., Blethrow, J. D., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252 · see citing works
Protein‐Reactive Natural Products
DRAHL, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500900 · Cited by 251 · see citing works
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242 · see citing works
Discovery of an allosteric site in the caspases
Hardy, J. A., Lam, J. W., Nguyen, J. T., O'Brien, T., & Wells, J. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404781101 · Cited by 236 · see citing works
Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
Jann, M. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.1.1.34664 · Cited by 236 · see citing works
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Kim, C. A., Peng, L. W. T., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234 · see citing works
Doehn, U., Hauge, C., Frank, S. R., Jensen, C. J., Duda, K., Nielsen, J. V., Cohen, M. S., Johansen, J. V., Winther, B. R., Lund, L. R., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.002 · Cited by 228 · see citing works
Evans, E. K., Tester, R. W., Aslanian, S., Karp, R., Sheets, M. P., Labenski, M., Witowski, S. R., Lounsbury, H. A., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 223 · see citing works
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb842 · Cited by 221 · see citing works
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Ho, C., Liao, W., Lin, C.-A., Shih, J., Yu, C., & Yang, J. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2231 · Cited by 219 · see citing works
Second-generation inhibitors of Bruton tyrosine kinase
Wu, J., Liu, C., Tsui, S. T., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0313-y · Cited by 216 · see citing works
RSK and MSK in MAP kinase signalling
Hauge, C., & Frödin, M. (2006) · Journal of Cell Science · doi:10.1242/jcs.02950 · Cited by 204 · see citing works
Progress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 200 · see citing works
Yocum, R. R., Rasmussen, J. R., & Strominger, J. L. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85621-1 · Cited by 194 · see citing works
The Future of Cysteine Cathepsins in Disease Management
Kramer, L., Türk, V., & Turk, B. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.003 · Cited by 194 · see citing works
Caspase inhibitors: viral, cellular and chemical
Callus, B. A., & Vaux, D. L. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402034 · Cited by 190 · see citing works
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Tiong, K. H., Mah, L. Y., & Leong, C. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0886-7 · Cited by 179 · see citing works
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 178 · see citing works
Nakamura, Y., Oka, M., Soda, H., Shiozawa, K., Yoshikawa, M., Itoh, A., Ikegami, Y., Tsurutani, J., Nakatomi, K., Kitazaki, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2417 · Cited by 177 · see citing works
Cheng, G., Ye, Z. S., & Baltimore, D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8152 · Cited by 171 · see citing works
Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170 · see citing works
A common allosteric site and mechanism in caspases
Scheer, J. M., Romanowski, M. J., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602571103 · Cited by 168 · see citing works
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153 · see citing works
Falgueyret, J., Desmarais, S., Oballa, R. M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0504961 · Cited by 152 · see citing works
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 148 · see citing works
Liao, B.-C., Lin, C., & Yang, J. C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 147 · see citing works
Bourne, Y., Radić, Z., Sulzenbacher, G., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603018200 · Cited by 140 · see citing works
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137 · see citing works
Identification and Characterization of an Irreversible Inhibitor of CDK2
Anscombe, E., Meschini, E., Mora-Vidal, R., Martin, M. P., Staunton, D., Geitmann, M., Danielson, U. H., Stanley, W. A., Wang, L.-Z., Reuillon, T. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.018 · Cited by 134 · see citing works
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 133 · see citing works
Targeting RAS-mutant cancers: is ERK the key?
Ryan, M. B., Der, C., Wang-Gillam, A., & Cox, A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 125 · see citing works
Back to the roots: the remarkable RAF oncogene story
Zebisch, A., & Troppmair, J. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6005-y · Cited by 124 · see citing works
The Molecular Perspective: The ras Oncogene
Goodsell, D. S. (1999) · Stem Cells · doi:10.1002/stem.170235 · Cited by 124 · see citing works
Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121 · see citing works
Rupanagudi, K. V., Kulkarni, O. P., Lichtnekert, J., Darisipudi, M. N., Mulay, S. R., Schott, B., Grüner, S., Haap, W. J., Hartmann, G. R., & Anders, H. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203717 · Cited by 114 · see citing works
Song, H., Jung, K. S., Yoo, K. H., Cho, J., Lee, J. Y., Lim, S. H., Kim, H. S., Sun, J., Lee, S., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.093 · Cited by 114 · see citing works
EGFR G796D mutation mediates resistance to osimertinib
Zheng, D., Hu, M., Bai, Y., Zhu, X., Lu, X., Wu, C., Wang, J., Liu, L., Wang, Z., Ni, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17913 · Cited by 111 · see citing works
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 108 · see citing works
Günther, M., Lategahn, J., Juchum, M., Döring, E., Keul, M., Engel, J., Tumbrink, H. L., Rauh, D., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00316 · Cited by 108 · see citing works
Smith, P. F., Krishnarajah, J., Nunn, P. A., Hill, R. J., Karr, D. E., Tam, D., Masjedizadeh, M. R., Funk, J. O., & Gourlay, S. G. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13351 · Cited by 108 · see citing works
Brameld, K. A., Owens, T. D., Verner, E. J., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 104 · see citing works
Azepanone-Based Inhibitors of Human and Rat Cathepsin K
Marquis, R. W., Ru, Y., LoCastro, S. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000481x · Cited by 102 · see citing works
The potential for caspases in drug discovery.
MacKenzie, S. H., Schipper, J. L., & Clark, A. C. (2010) · PubMed · Cited by 96 · see citing works
Cheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 96 · see citing works
Novel ALK inhibitors in clinical use and development
Iragavarapu, C., Mustafa, M., Akinleye, A., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0122-8 · Cited by 92 · see citing works
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Nacht, M., Qiao, L., Sheets, M. P., Martin, T. S., Labenski, M., Mazdiyasni, H., Karp, R., Zhu, Z., Chaturvedi, P., Bhavsar, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3008745 · Cited by 90 · see citing works
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90 · see citing works
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 85 · see citing works
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys
Jerome, C. P., Missbach, M., & Gamse, R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1529-x · Cited by 82 · see citing works
Yoshimura, N., Kudoh, S., Kimura, T., Mitsuoka, S., Matsuura, K., Hirata, K., Matsui, K., Negoro, S., Nakagawa, K., & Fukuoka, M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.10.006 · Cited by 81 · see citing works
Ibrutinib for B cell malignancies
Novero, A., Ravella, P. M., Chen, Y., Dous, G. V., & Liu, D. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-4 · Cited by 79 · see citing works
Baugh, M. D., Black, D., Westwood, P., et al. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.01.003 · Cited by 75 · see citing works
Reversible Covalent Inhibition of a Protein Target
Lee, C., & Grossmann, T. N. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203341 · Cited by 73 · see citing works
Effect of Cathepsin K Inhibitor Basicity on in Vivo Off-Target Activities
Desmarais, S., Black, W. C., Oballa, R. M., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.039511 · Cited by 73 · see citing works
Wang, Z., Watt, W., Brooks, N. A., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.007 · Cited by 72 · see citing works
Gao, X. Y., Le, X., & Costa, D. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162103 · Cited by 72 · see citing works
Wang, Y., Xiang, G., Kourouma, F., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706784 · Cited by 71 · see citing works
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Schettino, C., Bareschino, M. A., Ricci, V., & Ciardiello, F. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.2.167 · Cited by 70 · see citing works
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Aalipour, A., & Advani, R. H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12573 · Cited by 69 · see citing works
Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 68 · see citing works
Brömme, D., Panwar, P., & Turan, S. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1160884 · Cited by 64 · see citing works
Cuello, F., Snabaitis, A. K., Cohen, M. S., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.029900 · Cited by 63 · see citing works
Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 63 · see citing works
Preclinical Pharmacology of Metrifonate
Jann, M. W. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03879.x · Cited by 61 · see citing works
Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
Hendriks, R. W., Bredius, R. G. M., Pike‐Overzet, K., & Staal, F. J. T. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.585971 · Cited by 59 · see citing works
A kinase sequence database: sequence alignments and family assignment
Buzko, O., & Shokat, K. M. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.9.1274 · Cited by 58 · see citing works
Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis
Yang, H., Kala, M., Scott, B. G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1729 · Cited by 58 · see citing works
Mutant HRAS as novel target for MEK and mTOR inhibitors
Kiessling, M., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015) · OncoTarget · doi:10.18632/oncotarget.5619 · Cited by 57 · see citing works
Houde, V. P., Ritorto, M. S., Gourlay, R., Varghese, J., Davies, P., Shpiro, N., Sakamoto, K., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20131324 · Cited by 56 · see citing works
Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
Joharapurkar, A. A., Jain, M. R., & Dhanesha, N. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s56924 · Cited by 55 · see citing works
Discovery of a potent dual ALK and EGFR T790M inhibitor
Jang, J., Son, J. B., To, C., Bahcall, M., Kim, S. Y., Kang, S. Y., Mushajiang, M., Lee, Y., Janne, P. A., Choi, H. G., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.079 · Cited by 52 · see citing works
Yotsuji, A., Mitsuyama, J., Hori, R., et al. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.12.1848 · Cited by 51 · see citing works
Drug for an 'undruggable' protein
Baker, N. M., & Der, C. J. (2013) · Nature · doi:10.1038/nature12248 · Cited by 49 · see citing works
Equilibrium reactions of n-butanethiol with some conjugated heteroenoid compounds
Pritchard, R. B., Lough, C. E., Currie, D. J., et al. (1968) · Canadian Journal of Chemistry · doi:10.1139/v68-128 · Cited by 49 · see citing works
Genetic and Pharmacological Evaluation of Cathepsin S in a Mouse Model of Asthma
Deschamps, K., Cromlish, W. A., Weicker, S., et al. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0392oc · Cited by 48 · see citing works
Desmarais, S., Massé, F., & Percival, M. D. (2009) · Biological Chemistry · doi:10.1515/bc.2009.092 · Cited by 46 · see citing works
Knoepfel, T. F., Furet, P., Mah, R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00485 · Cited by 44 · see citing works
Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign
Baillie, T. A. (2016) · Angewandte Chemie · doi:10.1002/ange.201601091 · Cited by 42 · see citing works
Novotny, C. J., Hamilton, G. L., McCormick, F. P., & Shokat, K. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00374 · Cited by 41 · see citing works
Allosteric modulation of caspases
Häcker, H.-G., Sisay, M. T., & Gütschow, M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.003 · Cited by 40 · see citing works
Fabbro, S. K., Smith, S. M., Dubovsky, J. A., Gru, A. A., & Jones, J. A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0457 · Cited by 40 · see citing works
Neise, D., Sohn, D., Stefanski, A., Goto, H., Inagaki, M., Wesselborg, S., Budach, W., Stühler, K., & Jänicke, R. U. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.386 · Cited by 38 · see citing works
ALK inhibitors and advanced non-small cell lung cancer (Review)
Rossi, A., Maione, P., Sacco, P. C., Sgambato, A., Casaluce, F., Ferrara, M. L., Palazzolo, G., Ciardiello, F., & Gridelli, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2475 · Cited by 37 · see citing works
Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib
Law, S., Andrault, P.-M., Aguda, A. H., Nguyen, N. T., Kruglyak, N., Brayer, G. D., & Brömme, D. (2017) · Biochemical Journal · doi:10.1042/bcj20160985 · Cited by 36 · see citing works
DRAHL, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie · doi:10.1002/ange.200500900 · Cited by 34 · see citing works
Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases
Andersen, J. L., Gesser, B., Funder, E. D., Nielsen, C. J. F., Gotfred‐Rasmussen, H., Rasmussen, M. K., Toth, R. L., Gothelf, K. V., Arthur, J. S. C., Iversen, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06787-w · Cited by 33 · see citing works
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M. A., Hunter, J., Kim, N. D., Xie, T., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201307387 · Cited by 31 · see citing works
Selective Inhibition of Mutant Ras Protein through Covalent Binding
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400233 · Cited by 29 · see citing works
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders
Castillo, J. J., Treon, S. P., & Davids, M. S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000170 · Cited by 29 · see citing works
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
Wu, J., Zhang, M., & Liu, D. (2016) · Oncotarget · doi:10.18632/oncotarget.12786 · Cited by 28 · see citing works
Brutons Tyrosine Kinase as a New Therapeutic Target
Uckun, F. M., Tibbles, H. E., & Vassilev, A. O. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007784111331 · Cited by 26 · see citing works
Discontinued neuropathic pain therapy between 2009–2015
Knežević, N. N., Cicmil, N., Knezevic, I., et al. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1099627 · Cited by 26 · see citing works
Rociletinib: has the TIGER lost a few of its stripes?
Dhingra, K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw140 · Cited by 26 · see citing works
Wu, H., Huang, Q., Qi, Z., Chen, Y., Wang, A., Chen, C., Liang, Q., Wang, J., Chen, W., Dong, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00482-4 · Cited by 23 · see citing works
Yasuhiro, T., Sawada, W., Klein, C., Kozaki, R., Hotta, S., & Yoshizawa, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1201567 · Cited by 22 · see citing works
Identification of Specific Tethered Inhibitors for Caspase‐5
Gao, J., & Wells, J. A. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01261.x · Cited by 17 · see citing works
Movement toward Optimization of CLL Therapy
Rai, K. R., & Barrientos, J. C. (2014) · New England Journal of Medicine · doi:10.1056/nejme1400599 · Cited by 11 · see citing works
Broides, A., Hadad, N., Levy, J., & Lévy, R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0046-z · Cited by 9 · see citing works
Let K-Ras activate its own inhibitor
Statsyuk, A. V. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0066-0 · Cited by 9 · see citing works
The contributions of Sidney D. Nelson to drug metabolism research
Baillie, T. A. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.985790 · Cited by 7 · see citing works
Selektive Inhibierung von mutiertem Ras‐Protein durch kovalent bindende Liganden
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie · doi:10.1002/ange.201400233 · Cited by 6 · see citing works
Cardiovascular pipeline decline quantified
Mullard, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.208 · Cited by 5 · see citing works
Reversible und kovalente Inhibition eines Zielproteins
Lee, C., & Grossmann, T. N. (2012) · Angewandte Chemie · doi:10.1002/ange.201203341 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 142
- [1]Baillie TA, Angew Chem Int Ed Engl 2016, 55, 13408– 13421. 27539547
- [2]Singh J, Petter RC, Baillie TA, Whitty A, Nat Rev Drug Discov 2011, 10, 307– 317. 21455239
- [3]Roth GJ, Stanford N, Majerus PW, Proc Natl Acad Sci U S A 1975, 72, 3073– 3076. 810797 PMC432922
- [4]Picot D, Loll PJ, Garavito RM, Nature 1994, 367, 243– 249; P. J. Loll, D. Picot, R. M. Garavito, Nat Struct Biol 1995, 2, 637–643. 8121489
- [5]Baillie TA, Drug Metab Rev 2015, 47, 4– 11. 25410914
- [6]Yocum RR, Rasmussen JR, Strominger JL, J Biol Chem 1980, 255, 3977– 3986. 7372662
- [7]Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL, Proc Natl Acad Sci U S A 2012, 109, 11663– 11668. 22753474 PMC3406822
- [8]Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J, J Antibiot (Tokyo) 1979, 32, 1– 12. 761989
- [9]Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S, Antimicrob Agents Chemother 1988, 32, 1848– 1853. 3266730 PMC176031
- [10]Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB, J Pharmacol Exp Ther 1973, 187, 195– 202. 4746327
- [11]Bauer RA, Drug Discov Today 2015, 20, 1061– 1073. 26002380
- [12]Awoonor-Williams E, Walsh AG, Rowley CN, Biochim Biophys Acta Proteins Proteom 2017, 1865, 1664– 1675. 28528876
- [13]Zhang J, Yang PL, Gray NS, Nat Rev Cancer 2009, 9, 28– 39. 19104514 PMC12406740
- [14]Stamos J, Sliwkowski MX, Eigenbrot C, J Biol Chem 2002, 277, 46265– 46272. 12196540
- [15]Gazdar AF, Oncogene 2009, 28 Suppl 1, S24– 31. 19680293 PMC2849651
- [16]Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S, Cancer Res 2005, 65, 1541– 1546. 15735043
- [17]Schettino C, Bareschino MA, Ricci V, Ciardiello F, Expert Rev Respir Med 2008, 2, 167– 178. 20477246
- [18]Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, Almaden C, Nagata A, Ryan K, Feng J, Dalvie D, Kath JC, Xu M, Wani R, Murray BW, Proc Natl Acad Sci U S A 2014, 111, 173– 178. 24347635 PMC3890870
- [19]Singh J, Dobrusin EM, Fry DW, Haske T, Whitty A, McNamara DJ, J Med Chem 1997, 40, 1130– 1135. 9089334
- [20]Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM, Proc Natl Acad Sci U S A 1998, 95, 12022– 12027. 9751783 PMC21758
- [21]Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Janne PA, Cancer Res 2007, 67, 11924– 11932. 18089823
- [22]Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M, Lung Cancer 2006, 51, 363– 368. 16364494
- [23]Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC, J Clin Oncol 2010, 28, 3076– 3083. 20479403
- [24]Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W, Cancer Discov 2014, 4, 1036– 1045. 25074459 PMC4155006
- [25]Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Janne PA, Nature 2009, 462, 1070– 1074. 20033049 PMC2879581
- [26]Hernandes MZ, Cavalcanti SM, Moreira DR, de Azevedo Junior WF, Leite AC, Curr Drug Targets 2010, 11, 303– 314. 20210755
- [27]Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Brewer M. Red, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W, Cancer Discov 2014, 4, 1046– 1061. 24893891 PMC4315625
- [28]Yosaatmadja Y, Silva S, Dickson JM, Patterson AV, Smaill JB, Flanagan JU, McKeage MJ, Squire CJ, J Struct Biol 2015, 192, 539– 544. 26522274
- [29]Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, Investigators A, N Engl J Med 2017, 376, 629– 640. 27959700 PMC6762027
- [30]Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR, Nat Med 2015, 21, 560– 562. 25939061 PMC4771182
- [31]Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M, Nat Commun 2016, 7, 11815; H. N. Song, K. S. Jung, K. H. Yoo, J. Cho, J. Y. Lee, S. H. Lim, H. S. Kim, J. M. Sun, S. H. Lee, J. S. Ahn, K. Park, Y. L. Choi, W. Park, M. J. Ahn, J Thorac Oncol 2016, 11, e45–47. 27283993 PMC4906406
- [32]Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Janne PA, Meyerson M, Marto JA, Engen JR, Gray NS, Angew Chem Int Ed Engl 2014, 53, 199– 204. 24259466 PMC3914205
- [33]Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, Soria JC, Ann Oncol 2015, 26, 2073– 2078. 26269204
- [34]Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Chih-Hsin Yang J, J Thorac Oncol 2017, 12, 567– 572. 27923714
- [35]Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C, Wang J, Liu L, Wang Z, Ni J, Yang Z, Xu J, Oncotarget 2017, 8, 49671– 49679. 28572531 PMC5564797
- [36]Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KKC, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr STM, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin M-J, Zientek M, Zhou R, Kath JC, J Med Chem 2016, 59, 2005– 2024. 26756222
- [37]Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Pferdekamper AC, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, DiDonato M, Bursulaya B, Lelais G, Barretina J, McNeill M, Epple R, Marsilje TH, Pathan N, Engelman JA, Michellys PY, McNamara P, Harris J, Bender S, Kasibhatla S, Cancer Res 2016, 76, 1591– 1602. 26825170
- [38]Wang S, Cang S, Liu D, J Hematol Oncol 2016, 9, 34. 27071706 PMC4830020
- [39]Liao BC, Lin CC, Yang JC, Curr Opin Oncol 2015, 27, 94– 101. 25611025
- [40]Zhang L, Zhao H, Hu B, Jiang J, Zheng X, Zhang Y, Ma Y, Ge J, Zou B, Fang X, Xu W, Xu X, Ann Oncol 2016, 27, 359O– 359O; X. Xu, Chin J Cancer 2015, 34, 285–287.26658890
- [41]Gunther M, Lategahn J, Juchum M, Doring E, Keul M, Engel J, Tumbrink HL, Rauh D, Laufer S, J Med Chem 2017, 60, 5613– 5637. 28603991
- [42]Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A, Cancer Discov 2013, 3, 1404– 1415. 24065731 PMC4048995
- [43]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J, Eur J Cancer 2009, 45, 228– 247. 19097774
- [44]Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR, N Engl J Med 2015, 372, 1700– 1709. 25923550
- [45]Dhingra K, Ann Oncol 2016, 27, 1161– 1164. 27045101
- [46]Novero A, Ravella PM, Chen Y, Dous G, Liu D, Exp Hematol Oncol 2014, 3, 4; A. Aalipour, R. H. Advani, Br J Haematol 2013, 163, 436–443; R. H. Advani, J. J. Buggy, J. P. Sharman, S. M. Smith, T. E. Boyd, B. Grant, K. S. Kolibaba, R. R. Furman, S. Rodriguez, B. Y. Chang, J. Sukbuntherng, R. Izumi, A. Hamdy, E. Hedrick, N. H. Fowler, J Clin Oncol 2013, 31, 88–94. 24472371 PMC3913970
- [47]Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M,, Nature 1993, 361, 226– 233; R. W. Hendriks, R. G. Bredius, K. Pike-Overzet, F. J. Staal, Expert Opin Ther Targets 2011, 15, 1003–1021. 8380905
- [48]Uckun FM, Tibbles HE, Vassilev AO, Anticancer Agents Med Chem 2007, 7, 624– 632. 18045057
- [49]Broides A, Hadad N, Levy J, Levy R, J Clin Immunol 2014, 34, 555– 560; J. J. Castillo, S. P. Treon, M. S. Davids, Cancer J 2016, 22, 34–39. 24771458
- [50]Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA, JAMA Oncol 2015, 1, 684– 686; G. Cheng, Z. S. Ye, D. Baltimore, Proc Natl Acad Sci U S A 1994, 91, 8152–8155. 26182170
- [51]Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z, J Med Chem 2014, 57, 5112– 5128. 24915291
- [52]Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, Wang YL, N Engl J Med 2014, 370, 2352– 2354. 24869597 PMC4512173
- [53]Wu J, Liu C, Tsui ST, Liu D, J Hematol Oncol 2016, 9, 80. 27590878 PMC5010774
- [54]Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR, N Engl J Med 2016, 374, 323– 332. 26641137 PMC4862586
- [55]Rai KR, Barrientos JC, N Engl J Med 2014, 370, 1160– 1162; C. Iragavarapu, M. Mustafa, A. Akinleye, M. Furqan, V. Mittal, S. Cang, D. Liu, J Hematol Oncol 2015, 8, 17. 24645950
- [56]Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J, Yu K, Hu C, Wang W, Liu X, Deng Y, Wang L, Wang B, Li X, Gray NS, Liu J, Wei W, Liu Q, Sci Rep 2017, 7, 466. 28352114 PMC5428509
- [57]Yasuhiro T, Sawada W, Klein C, Kozaki R, Hotta S, Yoshizawa T, Leuk Lymphoma 2017, 58, 699– 707; J. Wu, M. Zhang, D. Liu, Oncotarget 2017, 8, 7201–7207. 27684575
- [58]Smith PF, Krishnarajah J, Nunn PA, Hill RJ, Karr D, Tam D, Masjedizadeh M, Funk JO, Gourlay SG, Br J Clin Pharmacol 2017, 83, 2367– 2376; J. K. Park, J. Y. Byun, J. A. Park, Y. Y. Kim, Y. J. Lee, J. I. Oh, S. Y. Jang, Y. H. Kim, Y. W. Song, J. Son, K. H. Suh, Y. M. Lee, E. B. Lee, Arthritis Res Ther 2016, 18, 91. 28636208 PMC5651318
- [59]Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF, J Pharmacol Exp Ther 2013, 346, 219– 228. 23709115
- [60]Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S, Budach W, Stuhler K, Janicke RU, Cell Death Dis 2013, 4, e859. 24136223 PMC3920941
- [61]Hauge C, Frodin M, J Cell Sci 2006, 119, 3021– 3023. 16868029
- [62]Cuello F, Snabaitis AK, Cohen MS, Taunton J, Avkiran M, Mol Pharmacol 2007, 71, 799– 806. 17142297
- [63]Houde VP, Ritorto MS, Gourlay R, Varghese J, Davies P, Shpiro N, Sakamoto K, Alessi DR, Biochem J 2014, 458, 41– 56. 24295069 PMC3898322
- [64]Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N, EMBO J 2006, 25, 2781– 2791. 16763566 PMC1500846
- [65]Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Taunton J, Hansen SH, Frodin M, Mol Cell 2009, 35, 511– 522. 19716794 PMC3784321
- [66]Wang Y, Xiang GS, Kourouma F, Umar S, Br J Pharmacol 2006, 148, 814– 824. 16751795 PMC1617077
- [67]Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM, Chem Biol 1999, 6, 671– 678; O. Buzko, K. M. Shokat, Bioinformatics 2002, 18, 1274–1275. 10467133
- [68]Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J, Mol Cell 1999, 3, 639– 648. 10360180
- [69]Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA, Nat Rev Drug Discov 2011, 10, 292– 306. 21455238
- [70]Cohen MS, Zhang C, Shokat KM, Taunton J, Science 2005, 308, 1318– 1321. 15919995 PMC3641834
- [71]Serafimova IM, Pufall MA, Krishnan S, Duda K, Cohen MS, Maglathlin RL, McFarland JM, Miller RM, Frodin M, Taunton J, Nat Chem Biol 2012, 8, 471– 476. 22466421 PMC3657615
- [72]Andersen JL, Gesser B, Funder ED, Nielsen CJF, Gotfred-Rasmussen H, Rasmussen MK, Toth R, Gothelf KV, Arthur JSC, Iversen L, Nissen P, Nat Commun 2018, 9, 4344. 30341347 PMC6195510
- [73]Zhao Z, Bourne PE, Drug Discov Today 2018, 23, 727– 735. 29337202
- [74]Tiong KH, Mah LY, Leong CO, Apoptosis 2013, 18, 1447– 1468. 23900974 PMC3825415
- [75]Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M, Settleman J, Gray NS, Chem Biol 2010, 17, 285– 295. 20338520 PMC2920453
- [76]Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Porta D. Graus, J Med Chem 2011, 54, 7066– 7083. 21936542
- [77]Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T, Cancer Res 2012, 72, 2045– 2056. 22369928
- [78]Schuttelkopf AW, van Aalten DM, Acta Crystallogr D Biol Crystallogr 2004, 60, 1355– 1363; V. Chell, K. Balmanno, A. S. Little, M. Wilson, S. Andrews, L. Blockley, M. Hampson, P. R. Gavine, S. J. Cook, Oncogene 2013, 32, 3059–3070. 15272157
- [79]Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J, Loughhead DG, Ton T, Karr DE, Gerritsen ME, Goldstein DM, Funk JO, J Med Chem 2017, 60, 6516– 6527. 28665128
- [80]Knoepfel T, Furet P, Mah R, Buschmann N, Leblanc C, Ripoche S, Graus-Porta D, Wartmann M, Galuba I, Fairhurst RA, ACS Med Chem Lett 2018, 9, 215– 220. 29541363 PMC5846040
- [81]Lim S, Kaldis P, Development 2013, 140, 3079– 3093. 23861057
- [82]Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Wang L, Whitfield HJ, Nat Struct Biol 2002, 9, 745– 749. 12244298
- [83]Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ, Chem Biol 2015, 22, 1159– 1164. 26320860 PMC4579270
- [84]Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS, Nature 2014, 511, 616– 620. 25043025 PMC4244910
- [85]Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS, Nat Chem Biol 2016, 12, 876– 884. 27571479 PMC5033074
- [86]Nacht M, Qiao L, Sheets MP, St Martin T, Labenski M, Mazdiyasni H, Karp R, Zhu Z, Chaturvedi P, Bhavsar D, Niu D, Westlin W, Petter RC, Medikonda AP, Singh J, J Med Chem 2013, 56, 712– 721. 23360348
- [87]Pritchard RB, Lough CE, Currie DJ, Holmes HL, Can J Chem 1968, 46, 775–+.
- [88]Lee CU, Grossmann TN, Angew Chem Int Ed Engl 2012, 51, 8699– 8700. 22806944
- [89]Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J, Nat Chem Biol 2015, 11, 525– 531. 26006010 PMC4472506
- [90]Goodsell DS, Stem Cells 1999, 17, 235– 236. 10437988
- [91]Ryan MB, Der CJ, Wang-Gillam A, Cox AD, Trends Cancer 2015, 1, 183– 198. 26858988 PMC4743050
- [92]Downward J, Nat Rev Cancer 2003, 3, 11– 22. 12509763
- [93]Ostrem JM, Shokat KM, Nat Rev Drug Discov 2016, 15, 771– 785. 27469033
- [94]Ahearn IM, Haigis K, Bar-Sagi D, Philips MR, Nat Rev Mol Cell Bio 2012, 13, 39– 51. PMC3879958 22189424
- [95]Baker NM, Der CJ, Nature 2013, 497, 577– 578. 23698372 PMC4902159
- [96]Novotny CJ, Hamilton GL, McCormick F, Shokat KM, ACS Chem Biol 2017, 12, 1956– 1962. 28530791 PMC6070134
- [97]Rudolph J, Stokoe D, Angew Chem Int Ed Engl 2014, 53, 3777– 3779. 24590864
- [98]Zebisch A, Troppmair J, Cell Mol Life Sci 2006, 63, 1314– 1330. 16649144 PMC11136008
- [99]Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM, Nature 2013, 503, 548– 551. 24256730 PMC4274051
- [100]Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD, Proc Natl Acad Sci U S A 2014, 111, 8895– 8900. 24889603 PMC4066474
- [101]Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y, Cancer Discov 2016, 6, 316– 329. 26739882
- [102]Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y, Cell 2018, 172, 578– 589 e517. 29373830
- [103]Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP, Nat Struct Mol Biol 2018, 25, 454– 462; A. V. Statsyuk, Nat Struct Mol Biol 2018, 25, 435–437. 29760531
- [104]Baines AT, Xu D, Der CJ, Future Med Chem 2011, 3, 1787– 1808. 22004085 PMC3347641
- [105]Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G, Oncotarget 2015, 6, 42183– 42196. 26544513 PMC4747218
- [106]Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S, Proc Natl Acad Sci U S A 2013, 110, 4015– 4020. 23431193 PMC3593920
- [107]Jann MW, Pharmacotherapy 2000, 20, 1– 12. 10641971
- [108]Polinsky RJ, Clin Ther 1998, 20, 634– 647. 9737824
- [109]Bourne Y, Radic Z, Sulzenbacher G, Kim E, Taylor P, Marchot P, J Biol Chem 2006, 281, 29256– 29267. 16837465
- [110]Jann MW, Pharmacotherapy 1998, 18, 55– 67; discussion 79–82. 9543466
- [111]Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D, Biochim Biophys Acta 2012, 1824, 68– 88. 22024571 PMC7105208
- [112]Palermo C, Joyce JA, Trends Pharmacol Sci 2008, 29, 22– 28. 18037508
- [113]Desmarais S, Masse F, Percival MD, Biol Chem 2009, 390, 941– 948. 19453281
- [114]Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K, Proksch J, Ward K, Smith B, Levy M, Cummings MD, Haltiwanger RC, Trescher G, Wang B, Hemling ME, Quinn CJ, Cheng HY, Lin F, Smith WW, Janson CA, Zhao B, McQueney MS, D’Alessio K, Lee CP, Marzulli A, Dodds RA, Blake S, Hwang SM, James IE, Gress CJ, Bradley BR, Lark MW, Gowen M, Veber DF, J Med Chem 2001, 44, 1380– 1395. 11311061
- [115]Jerome C, Missbach M, Gamse R, Osteoporos Int 2011, 22, 3001– 3011. 21308366
- [116]Kramer L, Turk D, Turk B, Trends Pharmacol Sci 2017, 38, 873– 898. 28668224
- [117]Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, Duong LT, Pickarski M, Percival MD, Mol Pharmacol 2008, 73, 147– 156; J. P. Falgueyret, S. Desmarais, R. Oballa, W. C. Black, W. Cromlish, K. Khougaz, S. Lamontagne, F. Masse, D. Riendeau, S. Toulmond, M. D. Percival, J Med Chem 2005, 48, 7535–7543. 17940194
- [118]Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA, J Bone Miner Res 2010, 25, 937– 947. 19874198
- [119]Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Therien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC, Bioorg Med Chem Lett 2008, 18, 923– 928. 18226527
- [120]Law S, Andrault PM, Aguda AH, Nguyen NT, Kruglyak N, Brayer GD, Bromme D, Biochem J 2017, 474, 851– 864. 28049758
- [121]Mullard A, Nat Rev Drug Discov 2016, 15, 669. 27681785
- [122]Bromme D, Panwar P, Turan S, Expert Opin Drug Discov 2016, 11, 457– 472. 27001692
- [123]Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, Hamilton W, Dempster M, Claxton C, Cai J, Bennett J, Long C, McKinnon H, Vink P, den Hoed L, Gorecka M, Vora K, Grant E, Percival MD, Boots AM, van Lierop MJ, J Autoimmun 2011, 36, 201– 209; K. Deschamps, W. Cromlish, S. Weicker, S. Lamontagne, S. L. Huszar, J. Y. Gauthier, J. S. Mudgett, A. Guimond, R. Romand, N. Frossard, M. D. Percival, D. Slipetz, C. M. Tan, Am J Respir Cell Mol Biol 2011, 45, 81–87; H. Yang, M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, P. Christadoss, J Immunol 2005, 174, 1729–1737. 21439785
- [124]Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B, Curr Pharm Des 2007, 13, 387– 403. 17311556
- [125]Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ, Ann Rheum Dis 2015, 74, 452– 463. 24300027
- [126]Knezevic NN, Cicmil N, Knezevic I, Candido KD, Expert Opin Investig Drugs 2015, 24, 1631– 1646. 26472477
- [127]Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I, Babes L, Reinheckel T, Peters C, Zeiser R, Bogyo M, Turk V, Psakhye SG, Turk B, Vasiljeva O, Nat Nanotechnol 2011, 6, 594– 602. 21822252
- [128]Wang Z, Watt W, Brooks NA, Harris MS, Urban J, Boatman D, McMillan M, Kahn M, Heinrikson RL, Finzel BC, Wittwer AJ, Blinn J, Kamtekar S, Tomasselli AG, Biochim Biophys Acta 2010, 1804, 1817– 1831. 20580860
- [129]MacKenzie SH, Schipper JL, Clark AC, Curr Opin Drug Discov Devel 2010, 13, 568– 576. PMC3289102 20812148
- [130]Shi Y, Protein Sci 2004, 13, 1979– 1987. 15273300 PMC2279816
- [131]Callus BA, Vaux DL, Cell Death Differ 2007, 14, 73– 78. 16946729
- [132]Hacker HG, Sisay MT, Gutschow M, Pharmacol Ther 2011, 132, 180– 195; I. N. Lavrik, A. Golks, P. H. Krammer, J Clin Invest 2005, 115, 2665–2672. 21807025
- [133]Hardy JA, Lam J, Nguyen JT, O’Brien T, Wells JA, Proc Natl Acad Sci U S A 2004, 101, 12461– 12466. 15314233 PMC514654
- [134]Gao J, Wells JA, Chem Biol Drug Des 2012, 79, 209– 215; J. M. Scheer, M. J. Romanowski, J. A. Wells, Proc Natl Acad Sci U S A 2006, 103, 7595–7600. 22014003 PMC3271850
- [135]Gao X, Le X, Costa DB, Expert Rev Anticancer Ther 2016, 16, 383– 390. 26943236 PMC4940973
- [136]Drahl C, Cravatt BF, Sorensen EJ, Angew Chem Int Ed Engl 2005, 44, 5788– 5809. 16149114
- [137]Guerciolini R, Int J Obes Relat Metab Disord 1997, 21 Suppl 3, S12– 23. 9225172
- [138]Joharapurkar AA, Dhanesha NA, Jain MR, Diabetes Metab Syndr Obes 2014, 7, 73– 84. 24611021 PMC3944999
- [139]Flatt PR, Bailey CJ, Green BD, Front Biosci 2008, 13, 3648– 3660. 18508462
- [140]Barnett A, Int J Clin Pract 2006, 60, 1454– 1470. 17073841
- [141]Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Janne PA, Choi HG, Gray NS, Eur J Med Chem 2017, 136, 497– 510; A. Rossi, P. Maione, P. C. Sacco, A. Sgambato, F. Casaluce, M. L. Ferrara, G. Palazzolo, F. Ciardiello, C. Gridelli, Int J Oncol 2014, 45, 499–508; N. Karachaliou, R. Rosell, Cancer Biol Med 2014, 11, 173–181. 28528303 PMC5800871
- [142]Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Janne PA, Eck MJ, Nature 2016, 534, 129– 132; H. Patel, R. Pawara, A. Ansari, S. Surana, Eur J Med Chem 2017, 142, 32–47; A. R. Johnson, P. B. Kohli, A. Katewa, E. Gogol, L. D. Belmont, R. Choy, E. Penuel, L. Burton, C. Eigenbrot, C. Yu, D. F. Ortwine, K. Bowman, Y. Franke, C. Tam, A. Estevez, K. Mortara, J. Wu, H. Li, M. Lin, P. Bergeron, J. J. Crawford, W. B. Young, ACS Chem Biol 2016, 11, 2897–2907. 27251290 PMC4929832
Cited by
Sorted by citations
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · see citing works
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231 · see citing works
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136 · see citing works
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry
Guilinger, J. P., Archna, A., Augustin, M., Bergmann, A., Centrella, P. A., Clark, M. A., Cuozzo, J. W., Däther, M., Guié, M.-A., Habeshian, S., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116223 · Cited by 49 · see citing works
Bashore, C., Jaishankar, P., Skelton, N. J., Fuhrmann, J., Hearn, B. R., Liu, P. S., Renslo, A. R., & Dueber, E. C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00031 · Cited by 34 · see citing works
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14 · see citing works
- Authors
- Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R.
- Affiliations
- Texas A&M University (US)
- Corresponding author
- Liu, Wenshe Ray
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2019-03-26
- Volume
- 14
- Issue
- 9
- Pages
- 889-906
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- PMC
- PMC6816337
- OpenAlex
- W2918370785
- Cited by
- 265
- References
- 170
- Citations by year
- 2026: 28 · 2025: 28 · 2024: 30 · 2023: 36 · 2022: 47 · 2021: 53 · 2020: 37 · 2019: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM121584)
- Cancer Prevention and Research Institute of Texas (RP170797)
- Welch Foundation (A-1715)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- covalent inhibitors, covalent drug design, protein kinases, Ras proteins, enzyme inhibitors, drug safety, drug discovery
- MeSH terms
- Humans, United States, United States Food and Drug Administration, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review